

MC4 Human, Common cancers (3)

No.	Age	Sex	Organ	Diagnosis	pTNM	Stage		MCN4#	Tissue type**
1	62	F	Endometrium	adenocarcinoma	T3cN0M0	III C	.	.	6
2	52	F	Endometrium	adenocarcinoma, endometrioid type	T1bN0M0	I B	D**	.	6
3	57	F	Endometrium	adenocarcinoma, endometrioid type	T1bN0M0	I B	D**	.	6
4	35	F	Endometrium	adenocarcinoma, endometrioid type	T1b1N0M0	I B1	.	.	6
5	38	F	Endometrium	adenocarcinoma	T1aN0M0	I A	.	105	6
6	53	F	Endometrium	adenocarcinoma, endometrioid type	T2bN0M0	II B	.	106	6
7	41	F	Endometrium	adenocarcinoma, endometrioid type	T3aN0M0	III A	.	107	6
8	49	F	Endometrium	adenocarcinoma, endometrioid type	T1aN0M0	I A	D**	.	6
9	53	F	Endometrium	adenocarcinoma, endometrioid type	T2N0M0	II	D**	109	6
10	52	F	Endometrium	adenocarcinoma, endometrioid type	T1bN0M0	I B	.	110	6
11	68	F	Gallbladder	metastatic adenocarcinoma from stomach	.	IV	.	.	6
12	67	F	Gallbladder	adenocarcinoma, moderately differentiated	T4N0M0	III	.	112	6
13	52	F	Gallbladder	adenocarcinoma, poorly differentiated	T3N0M0	II A	.	113	6
14	54	F	Gallbladder	adenosquamous carcinoma	T3N0M1	IV	.	114	6
15	64	F	Gallbladder	adenocarcinoma, moderately differentiated	T3N1M0	II B	.	.	6
16	82	F	Gallbladder	adenocarcinoma, well differentiated	T4N0M1	IV	.	.	6
17	50	M	Gallbladder	adenocarcinoma, well differentiated	T2N1M0	II B	.	.	6
18	52	M	Gallbladder	adenocarcinoma, moderately differentiated	T3N0M0	II A	.	.	6
19	64	M	Gallbladder	adenocarcinoma, well differentiated	T2N0M0	I B	.	.	6
20	54	F	Gallbladder	adenocarcinoma, well differentiated	T2N0M0	I B	.	.	6
21	51	M	Larynx	squamous cell carcinoma, well differentiated	T4aN1M0	IV A	.	.	6
22	52	M	Larynx	squamous cell carcinoma, poorly differentiated	T4aN1M0	IV A	.	.	6
23	68	M	Larynx	adenoid cystic carcinoma, largely solid type	T4aN2bM0	IV A	.	123	6
24	71	M	Larynx	squamous cell carcinoma, moderately differentiated	T3N2bM0	IV A	.	.	6
25	50	M	Larynx	squamous cell carcinoma	T4aN0M0	IV A	.	125	6
26	61	F	Larynx	squamous cell carcinoma, moderately differentiated	T3N2bM0	IV A	.	126	6
27	69	M	Larynx	squamous cell carcinoma, well differentiated	T3N0M0	III	.	127	6
28	60	M	Epiglottis	squamous cell carcinoma, well differentiated	T4aN1M0	IV A	.	128	6
29	71	M	Oral cavity	squamous cell carcinoma, well differentiated	T4bNXM0	IV B	.	129	6
30	56	M	Larynx	squamous cell carcinoma, well differentiated	T3N0M0	III	.	130	6
31	64	F	Uterine cervix	squamous cell carcinoma	T1b1N0M0	I B1	I B*	.	6
32	59	F	Uterine cervix	squamous cell carcinoma	T2bN1M0	III B	II A*	132	6
33	56	F	Uterine cervix	adenosquamous cell carcinoma	T2aN0M0	II A	II B*	133	6
34	50	F	Uterine cervix	squamous cell carcinoma	T1b1N1M0	III B	II A*	.	6
35	51	F	Uterine cervix	squamous cell carcinoma	T3bN1M0	III B	II A*	135	6
36	32	F	Uterine cervix	squamous cell carcinoma	T1bN1M0	III B	II B*	.	6
37	42	F	Uterine cervix	squamous cell carcinoma	T1bN1M0	III B	II A*	.	6
38	63	F	Uterine cervix	squamous cell carcinoma	T2bN1M0	III B	II B*	.	6
39	42	F	Uterine cervix	squamous cell carcinoma	T1bN0M0	I B	II B*	.	6
40	71	F	Uterine cervix	squamous cell carcinoma	T2bN1M0	III B	II B*	140	6
41	26	M	Neck	malignant lymphoma, B cell origin	.	I	.	.	6
42	53	M	Bone, femur	malignant lymphoma, probably B cell origin	.	IV	.	.	6
43	83	M	Jejunum	malignant lymphoma, B cell origin	.	IV	.	.	6
44	43	M	Cecum	malignant lymphoma, B cell origin	.	I E	.	144	6
45	69	M	Stomach	malignant lymphoma, probably B cell origin	.	I E	.	145	6
46	63	M	Retroperitoneum	malignant lymphoma, probably B cell origin	.	I	.	.	6
47	49	M	Stomach	malignant lymphoma, B cell origin	.	II E	.	.	6
48	51	M	Testis	malignant lymphoma, probably B cell origin	.	I E	.	.	6
49	60	F	Stomach	malignant lymphoma, B cell origin	.	I E	.	149	6
50	69	M	Duodenum	malignant lymphoma, probably B cell origin	.	I E	.	.	6
51	66	M	Skin, sole	malignant melanoma	T4aNXXM	II B	.	.	6
52	44	F	Anus	malignant melanoma	.	.	.	152	6
53	20	M	Skin, toe	malignant melanoma	T3aN2bM0	III B	.	.	6
54	22	F	Skin, scalp	malignant melanoma	T4bNXM0	II C	.	154	6
55	53	M	Skin, hip	malignant melanoma	T4aN2bM0	III B	.	.	6
56	73	F	Skin, abdomen	malignant melanoma	T4aNXM1	IV	.	.	6
57	33	F	Skin, buttock	malignant melanoma	TXNXM1	IV	.	156	6
58	47	M	Skin, axilla	malignant melanoma	T4bNXM1	IV	.	.	6
59	74	F	Maxillary sinus	malignant melanoma	6
60	.	.	Carbon

#: The normal tissue in MCN4 of corresponding number is from the identical patient.

*, Clinical stage; **D (#2, 3, 8, 9). double ovary and endometrial cancers.

TNM and Stage: AJCC Cancer Staging Manual (6th Edition)

**Tissue type: see General information sheet.